Corvus Pharmaceuticals, Inc. CRVS
11.47 USD +0.10 (+0.88%)
At closeNov 11, 2026, 4:01 PM EST
11.47 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
11.25 Day range 11.76
6.50 52-week range 25.52
- YTD
- +48.96%
- 1 year
- +40.39%
News
seekingalpha.com Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product Corvus Pharmaceuticals offers a catalyst-rich, fully funded pipeline, highlighted by soquelitinib's potential for durable remission in atopic dermatitis and PTCL. Soquelitinib's post-treatment…
seekingalpha.com Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027 Corvus Pharmaceuticals maintains a "Strong Buy" rating, driven by soquelitinib's advancing clinical programs in r/r PTCL and autoimmune indications. The phase 3 trial for relapsed/refractory PTCL…
globenewswire.com Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership…
seekingalpha.com Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript
marketbeat.com What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call Corvus Pharmaceuticals NASDAQ: CRVS reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug,…
benzinga.com Corvus Pharma Q3 2026 Earnings Call Transcript Corvus Pharma (NASDAQ:CRVS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Corvus Pharma Q3 EPS $(0.22), Inline Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.22) per share which met the analyst consensus estimate. This is a 83.33 percent decrease over losses of $(0.12) per share from the same…
globenewswire.com Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious…
globenewswire.com Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a…
benzinga.com Corvus Pharma Q2 2026 Earnings Call Transcript Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought…
defenseworld.net Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy? Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price gapped up before the market opened on Tuesday. The stock had previously closed at $11.87, but opened at $12.37. Corvus…
benzinga.com Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of…
globenewswire.com Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in…
globenewswire.com Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership…
globenewswire.com Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated…
seekingalpha.com Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
marketbeat.com Corvus Pharmaceuticals Q2 Earnings Call Highlights Corvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected…
benzinga.com Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of…
globenewswire.com Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib's potential in atopic dermatitis and…
globenewswire.com Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
defenseworld.net Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 5.1% – Should You Buy? Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) were up 5.1% during mid-day trading on Friday. The company traded as high as $14.91 and last traded at $14.9910. 120,438 shares…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
fool.com Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026. This transaction marks Moore's first investment in the business.
globenewswire.com Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China SOUTH SAN FRANCISCO, Calif. , June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a…
seekingalpha.com Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
benzinga.com Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings Stocks traded higher with Dow Jones up by 1,000 points. Consumer discretionary shares rose while energy stocks fell. State Street Corp reported upbeat earnings.
benzinga.com Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Friday The Dow Jones index rose 700 points, Autoliv Inc (NYSE: ALV) reported strong results causing a jump in its shares by 8.4% to $120.77. Other big gainers included CRML, ABTC, MFI, BYND, RXT, SHMD,…
benzinga.com This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Earnings Scheduled For March 12, 2026 
benzinga.com Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Crude Oil Gains 2%; D.R. Horton Earnings Top Views 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Corvus Pharmaceuticals, Immunitybio, Acadia Healthcare And Other Big Stocks Moving Higher On Tuesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Earnings Scheduled For August 7, 2025 - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Earnings Scheduled For March 25, 2025
benzinga.com This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
- benzinga.com Earnings Scheduled For November 12, 2024